GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Shares Buyback Ratio %

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Shares Buyback Ratio % : -38.53 (As of Apr. 28, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Algernon Pharmaceuticals's current shares buyback ratio was -38.53%.


Algernon Pharmaceuticals Shares Buyback Ratio % Historical Data

The historical data trend for Algernon Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Shares Buyback Ratio % Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only -63.55 -192.19 -21.07 -40.78 -40.14

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.16 -1.18 -26.28 -8.42 -

Algernon Pharmaceuticals Shares Buyback Ratio % Calculation

Algernon Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Aug. 2022 ) - Shares Outstanding (EOP) (A: Aug. 2023 )) / Shares Outstanding (EOP) (A: Aug. 2022 )
=(11.257 - 15.7758) / 11.257
=-40.14%

Algernon Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Nov. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Aug. 2023 ) - Shares Outstanding (EOP) (A: Nov. 2023 )) / Shares Outstanding (EOP) (A: Aug. 2023 )
=(15.7758 - 15.7758) / 15.7758
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Headlines

From GuruFocus

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

By Stock market mentor Stock market mentor 01-11-2023

Algernon Pharmaceuticals Announces Launch of Rights Offering

By sperokesalga sperokesalga 03-21-2023